HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dialysate sodium prescription and blood pressure in hemodialysis patients.

AbstractBACKGROUND:
Diffusive sodium removal has been recommended to control hypertension in hemodialysis patients. Recent evidence on hospitalizations and mortality, however, challenged the benefit of lower dialysate sodium prescriptions and ignited a debate in the dialysis community. We therefore studied the relationship between dialysate sodium and blood pressure over the longer term.
METHODS:
We used multiply adjusted linear mixed models to estimate the association between dialysate sodium and predialysis systolic blood pressure (SBP) as well as change in SBP (delta SBP; postdialysis minus predialysis) in 23,962 patients from the international Dialysis Outcomes and Practice Patterns Study.
RESULTS:
We found that 43% of hemodialysis facilities had variable (individualized) dialysate sodium prescriptions (125-155 mEq/L), whereas 57% had uniform dialysate sodium prescriptions (135-145 mEq/L) for ≥90% patients. Between-group comparisons of these 2 facility types suggested that dialysate sodium, when variably prescribed, might have been used to modify predialysis SBP (P interaction = 0.01) and perhaps delta SBP levels (P interaction = 0.08). Within facilities not prone to indication bias, because dialysate sodium was not variable, higher uniform dialysate sodium (per 2 mEq/L) was associated with slightly higher SBP (+0.9 mm Hg, 95% confidence interval (CI) = 0.1-1.6 among all patients; +1.7 mm Hg, 95% CI = 0.1-3.2 among patients not treated with blood pressure medication) and no increase in delta SBP.
CONCLUSIONS:
Patients assigned to hemodialysis facilities with uniformly higher dialysate sodium do not have markedly higher predialysis SBP, providing rather limited support for lowering dialysate sodium to control hypertension, particularly in view of hospitalization and mortality risks associated with lower dialysate sodium.
AuthorsManfred Hecking, Angelo Karaboyas, Hugh Rayner, Rajiv Saran, Ananda Sen, Masaaki Inaba, Jürgen Bommer, Walter H Hörl, Ronald L Pisoni, Bruce M Robinson, Gere Sunder-Plassmann, Friedrich K Port
JournalAmerican journal of hypertension (Am J Hypertens) Vol. 27 Issue 9 Pg. 1160-9 (Sep 2014) ISSN: 1941-7225 [Electronic] United States
PMID24651636 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: [email protected].
Chemical References
  • Antihypertensive Agents
  • Dialysis Solutions
  • Sodium
Topics
  • Antihypertensive Agents (therapeutic use)
  • Blood Pressure (drug effects)
  • Dialysis Solutions (adverse effects, therapeutic use)
  • Female
  • Humans
  • Hypertension (blood, diagnosis, drug therapy, epidemiology, physiopathology)
  • Kidney Diseases (blood, diagnosis, epidemiology, physiopathology, therapy)
  • Linear Models
  • Male
  • Multivariate Analysis
  • Practice Patterns, Physicians'
  • Prescriptions
  • Prevalence
  • Prospective Studies
  • Renal Dialysis (adverse effects)
  • Risk Factors
  • Sodium (adverse effects, blood, therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: